Alpha 2.0
Login Register
» Articles » PMID: 39926854

Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia

Overview
Journal J Pharm Bioallied Sci
Date 2025 Feb 10
PMID 39926854
Authors
Awadh AlRashidi
Rasha AlArfaj
Abdullah Al Ruqaib
Emad Masuadi
Munirah AlFaraj
Yousef Al-Saleh
Rakan AlEnezi
Moeber M Mahzari
Mohammed Z Aljulifi
Affiliations
Soon will be listed here.
Abstract

Objective: This retrospective study aimed to determine the effect of liraglutide on weight and HbA1c levels in patients with type 2 diabetes mellitus (T2DM) in Saudi Arabia. The present investigation was carried out at a medical facility located in the Kingdom of Saudi Arabia.

Materials And Methods: A retrospective analysis was conducted on the clinical records of 290 patients who were diagnosed with T2DM and were above 18 years of age. These patients were administered liraglutide for a minimum of 6 months. The dataset comprised various parameters such as the duration of diabetes, duration of liraglutide therapy, weight, and multiple biochemical markers such as HbA1c and low-density lipoprotein cholesterol levels. These parameters were measured both before and after the administration of liraglutide therapy.

Results: The primary metrics evaluated in this study were alterations in body weight and levels of glycated hemoglobin (HbA1c). Over the 24-month observational period, significant reductions in body mass index (38.6 kg/m to 37 kg/m), body weight (99.3 kg to 96 kg), and HbA1c levels (8.9% to 7.8%) (all < 0.01) were seen.

Conclusion: Liraglutide reduced HbA1c levels and weight and affected multiple metabolic markers in patients with T2DM in a real-world setting in Saudi Arabia.

References
1.
Al Hayek A, Robert A, Al Dawish M . Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study. Clin Med Insights Endocrinol Diabetes. 2019; 12:1179551419834935. PMC: 6425521. DOI: 10.1177/1179551419834935. View
2.
Helmstadter J, Keppeler K, Aust F, Kuster L, Frenis K, Filippou K . GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation. Antioxidants (Basel). 2021; 10(8). PMC: 8388926. DOI: 10.3390/antiox10081175. View
3.
Martinez L, Penfornis A, Gautier J, Eschwege E, Charpentier G, Bouzidi A . Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing.... Adv Ther. 2017; 34(3):674-685. PMC: 5350193. DOI: 10.1007/s12325-017-0476-0. View
4.
Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X . Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020; 10(1):14790. PMC: 7478957. DOI: 10.1038/s41598-020-71908-9. View
5.
Albarkah Y, Tourkmani A, Bin Rsheed A, Al Harbi T, Ebeid Y, Bushnag R . Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia. J Family Med Prim Care. 2019; 8(6):1919-1924. PMC: 6618200. DOI: 10.4103/jfmpc.jfmpc_372_19. View